1. India's Obesity Drug Market Disrupted by Flood of Cheap Generic Versions of Novo Nordisk's Blockbuster
A wave of low-cost generic versions of Novo Nordisk's blockbuster weight-loss drug is rapidly reshaping India's fast-growing obesity treatment market. This surge of copycat medications introduces a powerful new competitive dynamic, putting significant pricing pressure on the original branded therapies and potentially e...